美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · GOSS近 30 天 11 則 · 第 1 / 1 頁
- Gossamer Bio Appoints Greg Ciongoli to Board of Directors
- Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
- Gossamer Bio Announces 1-for-80 Reverse Stock Split
- Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
- Gossamer Bio to Present at Cantor Global Healthcare Conference
- Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?
- Gossamer Bio announces $250m in funding to advance seralutinib
- Sector Update: Healthcare Stocks Advance in Afternoon Trading
- Gossamer Bio Secures Up to $250 Million Private Placement to Fund Seralutinib Through Potential FDA Approval
- Gossamer Bio Agrees to Up to $250 Million Private Placement; Shares Rise Pre-Bell
- Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
- Gossamer Bio (GOSS) Stock Sees Fair Value Cut As Analysts Split On Seralutinib
- Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
- Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
- Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update
- Update: Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment
- Gossamer Bio shares jump after FDA update and seralutinib rights return
- Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
- Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes
- Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。